Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma.
作者信息
Trappe Ralf, Budde Ulrich, Zimmermann Heiner
出版信息
Thromb Haemost. 2012 Oct;108(4):798-800. doi: 10.1160/TH12-05-0322. Epub 2012 Aug 23.
PMID:22918265
Abstract
摘要
相似文献
1
Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma.
Thromb Haemost. 2012 Oct;108(4):798-800. doi: 10.1160/TH12-05-0322. Epub 2012 Aug 23.
2
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27.
3
Don't miss the base - keratoacanthoma-type squamous cell carcinoma with perineural invasion during BRAF inhibitor therapy for melanoma.
J Dtsch Dermatol Ges. 2015 Dec;13(12):1279-81. doi: 10.1111/ddg.12686.
4
RASopathic alopecia: hair changes associated with vemurafenib therapy.
J Am Acad Dermatol. 2015 Apr;72(4):738-41. doi: 10.1016/j.jaad.2015.01.011.
5
Painful nipple hyperkeratosis secondary to vemurafenib.
Dermatol Ther. 2017 May;30(3). doi: 10.1111/dth.12477. Epub 2017 Feb 17.
6
The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.
J Invest Dermatol. 2010 Nov;130(11):2669-71. doi: 10.1038/jid.2010.177. Epub 2010 Jun 24.
7
Vemurafenib-induced DRESS.
JAMA Dermatol. 2013 Oct;149(10):1242-3. doi: 10.1001/jamadermatol.2013.5278.
8
Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
Melanoma Res. 2014 Feb;24(1):75-82. doi: 10.1097/CMR.0000000000000034.
9
Toxic epidermal necrolysis induced by vemurafenib.
Actas Dermosifiliogr. 2015 Oct;106(8):682-3. doi: 10.1016/j.ad.2015.03.008. Epub 2015 Jun 4.
10
Hepatotoxicity with combination of vemurafenib and ipilimumab.
N Engl J Med. 2013 Apr 4;368(14):1365-6. doi: 10.1056/NEJMc1302338.
Zotero 插件